Home › Research › Tau biomarkers
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow K, Hampel H, Weiner M, Zetterberg H.. Nature reviews. Neurology, 2010-02-16
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Intense multidisciplinary research has provided detailed knowledge of the molecular pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new therapeutic strategies with putative disease-modifying effects. Several of the most promising approaches, such as amyloid-beta immunotherapy and secretase inhibition, are now being tested in clinical trials.
What this study adds
Evidence grade: Low
This is a narrative review. This 2010 review covers biomarkers measured in cerebrospinal fluid and blood plasma.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature reviews. Neurology. https://doi.org/10.1038/nrneurol.2010.4
Vancouver
Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nature reviews. Neurology. 2010. doi:10.1038/nrneurol.2010.4. PMID: 20157306.
BibTeX
@article{blennow2010-20157306,
author = {Blennow, K. and Hampel, H. and Weiner, M. and Zetterberg, H.},
title = {{Cerebrospinal fluid and plasma biomarkers in Alzheimer disease}},
journal = {Nature reviews. Neurology},
year = {2010},
doi = {10.1038/nrneurol.2010.4},
pmid = {20157306},
url = {https://doi.org/10.1038/nrneurol.2010.4}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- This knowledge has been translated into new therapeutic strategies with putative disease-modifying effects.
- Several of the most promising approaches, such as amyloid-beta immunotherapy and secretase inhibition, are now being tested in clinical trials.
- Disease-modifying treatments might be at their most effective when initiated very early in the course of AD, before amyloid plaques and neurodegeneration become too widespread.
- Thus, biomarkers are needed that can detect AD in the predementia phase or, ideally, in presymptomatic individuals.
Why it matters
This 2010 review covers biomarkers measured in cerebrospinal fluid and blood plasma. Its stated reasoning is that disease-modifying treatments then in trials, such as amyloid-beta immunotherapy and secretase inhibition, "might be at their most effective when initiated very early", so "biomarkers are needed that can detect AD in the predementia phase or, ideally, in presymptomatic individuals." The summary held here stops before the review discusses specific biomarkers, and it reports no treatment results, so see the original paper for which tests it covers and how well they perform.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 57/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nature reviews. Neurology) |
| Journal's citation record | 3 / 4 | Nature Reviews Neurology: journal h-index 269 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2010 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,864 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 103.6 citations a year over 18 year(s) since 2010 |
| Impact for its field and year | 4 / 6 | Cited 17.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 5 / 6 | Cited by 146 other studies in this library |
| Still being cited | 4 / 4 | Cited 216 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Henrik Zetterberg: h-index 196 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, San Francisco: institution h-index 1,915 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20157306) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 57 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 57.
Later studies that cite this one
146 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Tau biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.